Pain and the genome
There is increasing evidence that genotype affects pain sensitivity and pain modulation. As an example in humans, 10% of a Caucasian population studied only poorly metabolized the liver isozyme P450IID6 (required for the O-demethylation of the widely used opiate drug codeine to morphine) . So, for such people codeine is an inefficient analgesic. The enzymatic defect is related to a mutation in the CYP2D6 gene . As an experimental example, a recent study in rats demonstrated that a form of stress-induced analgesia was naloxone-insensitive, but attenuated by dizocilpine in male C57BL/6J mice. The same type of analgesia in male DBA/2J mice was significantly attenuated by naloxone but was insensitive to dizocilpine antagonism, indicating the role exerted by the different rat strain (i.e., genetic factors) in determining the selective recruitment of alternative central mechanisms of pain inhibition .
KeywordsNerve Growth Factor Carpal Tunnel Syndrome CYP2D6 Gene Nerve Growth Factor Expression Hereditary Sensory Neuropathy
Unable to display preview. Download preview PDF.
- 5.Rubinstein M, Mogil IS, Japon M et al (1996) Absence of opioid stress-induced analgesia in mice lacking beta-endorphin by site-directed mutagenesis. Proc Natl Acad Sci 93(9).3995–4000Google Scholar
- 8.Levi Montalcini R (1987) The nerve growth factor: thiry five years later EMBO J 6.11451154Google Scholar
- 10.Hefti F, Hartikka J, Knusel B (1989) Function of neurotrophic factors in the adult and agin brain and their possible use in the treatment of neurodegenerative diseases Neurobiol Aging 10: 515–533Google Scholar
- 20.Devor M, Raber P (1991) Experimental evidence of a genetic predisposition to neuropathic pain. Eur J Pain 12 (3): 65–68Google Scholar